Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2009
11/03/2009CA2520450C Polymeric modifiers that improve the bioavailability of protein drugs and pharmaceutical compositions thereof
11/03/2009CA2418961C Anti-il-12 antibodies, compositions, methods and uses
11/03/2009CA2415476C Matrix controlled transdermal system for stabile derivatives of ace inhibitors
11/03/2009CA2385477C Pca3 messenger rna species in benign and malignant prostate tissues
11/03/2009CA2320991C Calorically dense nutritional composition
11/03/2009CA2205379C Yeast-based delivery vehicles
11/03/2009CA2191064C Pantropic neurotrophic factors
11/03/2009CA2187626C Aav-mediated delivery of dna to cells of the nervous system
11/03/2009CA2181548C Zinc finger protein derivatives and methods therefor
11/03/2009CA2174338C Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
11/03/2009CA2105618C Humanized antibodies to ganglioside gm2
10/2009
10/30/2009CA2699190A1 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
10/29/2009WO2009132231A2 Peptidyl diacylglycerides
10/29/2009WO2009132149A2 Treatment of conditions related to cecal ligation shock
10/29/2009WO2009132129A2 Isoform-specific insulin analogues
10/29/2009WO2009131850A2 Pai-1 expression and activity inhibitors for the treatment of ocular disorders
10/29/2009WO2009131740A2 Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
10/29/2009WO2009131698A2 PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
10/29/2009WO2009131696A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
10/29/2009WO2009131553A2 Methods of altering bone growth by administration of sost or wise antagonist or agonist
10/29/2009WO2009131548A1 Multimeric forms of antimicrobial peptides
10/29/2009WO2009131395A2 Angiogenic peptide
10/29/2009WO2009131191A1 Metastin derivative and use thereof
10/29/2009WO2009131166A1 Wnt signaling inhibitor comprising insulin-like growth factor-binding protein
10/29/2009WO2009130600A2 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
10/29/2009WO2009130515A2 Method and system for recording and promoting peripheral nerve regeneration
10/29/2009WO2009130394A1 Gastroresistant cyclosporin formulation
10/29/2009WO2009130256A2 Compositions and methods for preventing or treating aids
10/29/2009WO2009130208A1 Liver-specific nucleic acid regulatory elements and methods and use thereof
10/29/2009WO2009130181A2 Dry transglutaminase composition
10/29/2009WO2009129561A1 Anti-viral nutraceutical
10/29/2009WO2009105786A3 Treatment for oral disease
10/29/2009WO2009105723A3 Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
10/29/2009WO2009104911A3 Uses as agents for prophylaxis or treatment of cervical cancer
10/29/2009WO2009093880A3 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor
10/29/2009WO2009091994A3 Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
10/29/2009WO2009076506A3 Gamma glutamylcysteine treatment or prevention of oxidative injury
10/29/2009WO2009046856A3 Use of serorphin as a therapeutic agent
10/29/2009WO2009046824A3 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
10/29/2009WO2009043505A3 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
10/29/2009WO2009043504A3 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
10/29/2009WO2009040089A3 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
10/29/2009WO2009039996A3 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
10/29/2009WO2009039977A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection
10/29/2009WO2009037264A3 Colonic delivery of antimicrobial agents
10/29/2009WO2009033781A3 Use of k237 as therapeutic agent
10/29/2009WO2009033751A3 Use of leu-enkephalin as a therapeutic agent
10/29/2009WO2009033718A3 Use of anti -inflammatory peptide 1 as a therapeutic agent
10/29/2009WO2009021121A4 Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
10/29/2009WO2009020802A3 Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
10/29/2009WO2009009173A3 Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
10/29/2009WO2009005718A8 Polypeptide microparticles having sustained release characteristics, methods and uses
10/29/2009WO2008155558A3 Microspheres
10/29/2009US20090271881 Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
10/29/2009US20090270820 System and method for use of agent in combination with subatmospheric pressure tissue treatment
10/29/2009US20090270592 Purified TNFR preparations
10/29/2009US20090270591 Novel surface antigen
10/29/2009US20090270495 Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof
10/29/2009US20090270486 Human rnase iii and compositions and uses thereof
10/29/2009US20090270338 Diaryl-cyclylalkyl derivatives as calcium channel blockers
10/29/2009US20090270337 Composition Comprising Carbohydrates and Peptides which Comprise Tryptophan
10/29/2009US20090270335 Collyrium for dry eye
10/29/2009US20090270334 Neuronal differentiation inhibitor peptide and use thereof
10/29/2009US20090270333 Methods of using motilin homologs
10/29/2009US20090270332 Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
10/29/2009US20090270331 Multi-domain amphipathic helical peptides and methods of their use
10/29/2009US20090270330 Purified arabinogalactan-protein (agp) composition useful in the treatment psoriasis and other disorders
10/29/2009US20090270329 Methods of administering porcine b-domainless fviii
10/29/2009US20090270328 Methods of increasing cerebral blood flow
10/29/2009US20090270327 Lepidopteran-Active Bacillus Thuringiensis Delta-Endotoxin Compositions and Methods of Use
10/29/2009US20090270326 Cell Death Inhibitor
10/29/2009US20090270325 Growth factor
10/29/2009US20090270324 Complement depletion using recombinant human c-3 derivatives
10/29/2009US20090270323 Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
10/29/2009US20090270322 G protein coupled receptor antagonists and methods of activating and inhibiting g protein coupled receptors using the same
10/29/2009US20090270321 Over-expression of MPS-1 gene or its gene product(s) results in reduction in size of a variety of malignancies
10/29/2009US20090270320 Use of galectin-7 to promote the re-epithelialization of wounds
10/29/2009US20090270319 Pharmaceutical use of protein molecules immunologically correlated to diptheria toxin
10/29/2009US20090270318 High-affinity antagonists of elr-cxc chemokines
10/29/2009US20090270317 Pharmaceutical compositions comprising bioelastomer fusion proteins
10/29/2009US20090270316 Her-2 binding antagonists
10/29/2009US20090270315 Method of inhibiting angiogenesis by using ephrin b2
10/29/2009US20090270314 Polypeptide having anti-angiogenic activity
10/29/2009US20090270313 Method of Treatment for Ischemic Heart Disease
10/29/2009US20090270312 Hiv-i gp41 fusion peptides for immunomodulaltion
10/29/2009US20090270311 Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
10/29/2009US20090270310 Process for the preparation of a nutrient formulation
10/29/2009US20090270309 Use of lactoferrin fragments and hydrolysates
10/29/2009US20090270308 Controlled release implantable dispensing device and method
10/29/2009US20090269847 Self-assembling peptide amphiphiles and related methods for growth factor delivery
10/29/2009US20090269843 Hemopexin fusion proteins
10/29/2009US20090269806 Process for producing dipeptides
10/29/2009US20090269739 Kit for detection of telomerase reverse transcriptase nucleic acids
10/29/2009US20090269422 Methods for controlling angiogenesis and cell proliferation
10/29/2009US20090269413 Flowable collagen material for dural closure
10/29/2009US20090269406 Therapeutic uses of biocompatible biogel compositions
10/29/2009US20090269404 Crosslinked Gelatin Gel, Multilayered Structure, Carrier for Bioactive Factor, Preparation for Release of Bioactive Factor, and Their Production Methods
10/29/2009US20090269397 Targeted and high density drug loaded polymeric materials
10/29/2009US20090269394 Methods and compositions for treating onchomycosis
10/29/2009US20090269389 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
1 ... 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 ... 3163